Many clinicians prefer to treat onychomycosis systemically. However, systemic therapy may not be suitable for all onychomycosis patients due to drug interactions, side effects of oral medications, or comorbidities. Two topical agents (efinaconazole 10%in 2014 and luliconazole 5%in 2016) have recently been approved for treatment of onychomycosis in Japan. We investigated the efficacy of these topical agents at Teikyo University Mizonokuchi Hospital, Kanagawa, Japan. We conducted a retrospective survey among patients diagnosed with onychomycosis at our outpatient clinic and had been treated with either efinaconazole 10%solution or luliconazole 5%solution. Prior to commencement of treatment, the disease severity was evaluated using the Scoring Clinical Index for Onychomycosis (SCIO). Furthermore, the efficacies of these agents were evaluated using turbidity scoring at each visit to our outpatient clinic. Sixty-two patients (33 men, 29 women) applied efinaconazole 10%solution, and 72 patients (35 men, 37 women) applied luliconazole 5%solution. The mean SCIO scores were 18.1 and 17.4, respectively, and the mean 5-grade evaluation scores were 3.5 and 3.4, respectively. Complete cure rates were 40. 3%(25/62) and 33.3%(24/72), respectively. The mean durations of treatment were 15.4 months and 11.9 months, respectively. There were no serious side effects in either treatment group. There were no significant differences between the two agents in improvement scores as assessed by the Tukey’s test. Thus, efinaconazole 10%and luliconazole 5%topical solutions were effective for the treatment of onychomycosis. These topical agents may become important treatment options for this indication.
CITATION STYLE
Shimoyama, H., Kuwano, Y., & Sei, Y. (2019). Retrospective survey of treatment outcomes of efinaconazole 10% solution and luliconazole 5% solution for onychomycosis in our facility. Medical Mycology Journal, 60(4), 95–100. https://doi.org/10.3314/mmj.19-00009
Mendeley helps you to discover research relevant for your work.